Patrick Daly

Cancer Nursing Today nonprod

In a recent meta-analysis published in Frontiers in Immunology, researchers evaluated the safety and efficacy profile of vedolizumab for the prevention and treatment of gastrointestinal (GI) acute graft-versus-host disease (aGVHD). According to the study&rsquo;s lead author, Allen Cheng-Wei Li, vedolizumab was effective and safe for early-grade GI aGVHDThe analysis included 122 patients from 8 studies published to the PubMed, Embase, Web of Science, and Cochrane Library databases by May 2022. One study examined vedolizumab as GVHD prophylaxis, and the remainder examined vedolizumab as GVHD treatment. Researchers used bivariate and random-effects models to assess primary end points, including overall response, complete response, mortality, and adverse events with vedolizumab.<h3>Vedolizumab Effectively Treats GI aGVHD</h3>Reportedly, the use of <a href="https://medlineplus.gov/druginfo/meds/a614034.html">vedolizumab</a> for the treatment of GI aGVHD yielded a significantly greater objective response rate (ORR) at day 14 (ORR, 60.53; risk ratio [RR], 14.14; 95% CI, 2.95-67.71), day 28 (ORR, 50%; RR, 7.36; 95% CI, 2.14-25.37), and month 12 (ORR, 76.92%; RR, 13.66; 95% CI, 3.5-53.35) from baseline.In addition, vedolizumab led to significantly improved complete response (CR) rates at 12 months (CR, 27.27%; RR, 5.50; 95% CI, 1.01-29.95), although the authors noted that the CR at days 14 and 28 did not reach statistical significance. Vedolizumab as GVHD prophylaxis was not associated with any specific adverse events. Vedolizumab as GVHD treatment was associated with significantly increased risk of adverse events, including infections (RR, 7.55) and metabolic or nutritional consequences (RR, 9.0).The authors suggested that vedolizumab was safe and effective in patients with GI aGVHD, especially earlier in the course of GVHD. &ldquo;Further studies are warranted to elucidate its efficacy for the prophylaxis of GI aGVHD in patients undergoing [hematopoietic stem cell transplant],&rdquo; they concluded.Read More <a href="https://cancernursingtoday.com/page/gvhd">Recent Research on Graft-Versus-Host Disease</a>

Vedolizumab for GI Acute GVHD Prevention and Treatment

GVHD

Vedolizumab was safe and effective for GI aGVHD treatment, although its efficacy as GVHD prophylaxis was unclear. 

About Us

Editorial Policy

Authors

Advertising

eNewsletters

Contact Us

Contribute

Calendar of Events

Career Center

Blood Cancers Today

GU Oncology Now

DocWire News

MashupMD

Urban Health Today

Breast Cancer

Colorectal Cancer

GI Cancer

GU Cancer

Gynecologic Cancer Awareness Month

Gyn-Onc

Blood Cancer Awareness Month

Leukemia

Lymphoma

Myeloproliferative Neoplasms

Multiple Myeloma

Myelodysplastic Syndrome

Myelofibrosis

Sickle Cell

Hem/Onc

Professional Development

Patient Voice

Lung Cancer

Skin Cancer

Other Tumor Types

News

Treatment

More

Conferences

Calendar

CARE Award

Best Practices

Expert Interviews

Subscribe